COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 1549: Articles 15481-15490  | Next

COVID-19 outbreak rates and infection attack rates associated with the workplace: a descriptive epidemiological study
Chen, Y., Aldridge, T., UK COVID-19 National Core Studies Consortium, , Ferraro, C. F., Khaw, F.-M.
10.1101/2021.05.06.21256757 — Posted: 2021-05-14
Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.1.7 Variant
Toback, S., Heath, P. T., Galiza, E. P., Baxter, D., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., Goodman, A. L., Heer, A., Higham, A., Iyengar, S., Jamal, A., Jeanes, C., Kalra, P. A., Kyriakidou, C., McAuley, D. F., Meyrick, A., Minassian, A. M., Minton, J., Moore, P., Munsoor, I., Nicholls, H., Osanlou, O., Packham, J., Pretswell, C., San Francisco Ramos, A., Saralaya, D., Sheridan, R. P., Smith, R., Soiza, R. L., Swift, P. A., Thomson, E. C., Turner, J., Viljoen, M. E., Albert, G., Cho, I., Dubovsky, F., Glenn, G., Rivers, J., Robertson, A., S
10.1101/2021.05.13.21256639 — Posted: 2021-05-14 Discussion: Onsite | Offsite
Efficacy and Safety of Polyherbal formulation as an add-on to the standard of care in mild to moderate COVID-19: A randomized, double-blind, placebo-controlled trial
Patankar, S. B., Rangnekar, H., Joshi, K., Suryawanshi, K., Soni, P., Gorde, A., Shah, T., Patankar, S., Jha, D., Raje, R.
10.1101/2021.05.14.21256900 — Posted: 2021-05-14
Tyrosine Kinase Inhibitor Family of Drugs as Prospective Targeted Therapy for COVID-19 Based on In Silico And 3D-Human Vascular Lung Model Studies
Saxena, S., Meher, K., Rotella, M., Vangala, S., Chandran, S., Malhotra, N., Palakodeti, R., Voleti, S., Saxena, U.
10.1101/2021.05.13.443955 — Posted: 2021-05-14
in silico Assessment of Antibody Drug Resistance to Bamlanivimab of SARS-CoV-2 Variant B.1.617
Zhang, L., Huynh, T., Luan, B.
10.1101/2021.05.12.443826 — Posted: 2021-05-14
Glucosidase inhibitors suppress SARS-CoV-2 in tissue culture and may potentiate
Reyes, H., Du, Y., Zhou, T., Xie, X., Shi, P.-Y., Weiss, S. R., Block, T.
10.1101/2021.05.14.444190 — Posted: 2021-05-14
Isolation and characterization of SARS-CoV-2 VOC, 20H/501Y.V2, from UAE travelers
Yadav, P., Sarkale, P., Razdan, A., Gupta, N., Nyayanit, D., Sahay, R., Potdar, V., Patil, D., Baradkar, S., Kumar, A., Aggarwal, N., Shete, A., Kaur, H.
10.1101/2021.05.14.443968 — Posted: 2021-05-14
SARS-CoV-2 Variant of Concern Substitutions Alter Spike Glycoprotein Receptor Binding Domain Structure and Stability
Moss, D. L., Rappaport, J.
10.1101/2021.05.11.443443 — Posted: 2021-05-14
Common Mechanism of SARS-CoV and SARS-CoV-2 Pathogenesis across Species
Schafer, A., Gralinski, L. E., Leist, S. R., Winkler, E. S., Hampton, B. K., Mooney, M. A., Jensen, K. L., Graham, R. L., Agnihothram, S., Jeng, S., Chamberlin, S., Bell, T. A., Scobey, D. T., VanBlargan, L. A., Thackray, L. B., Hock, P., Miller, D. R., Shaw, G. D., Pardo Manuel de Villena, F., McWeeney, S. K., Montgomery, S. A., Diamond, M. S., Heise, M. T., Menachery, V. D., Ferris, M. T., Baric, R. S.
10.1101/2021.05.14.444205 — Posted: 2021-05-14
Siglec-1 on dendritic cells mediates SARS-CoV-2 trans-infection of target cells while on macrophages triggers proinflammatory responses
Perez-Zsolt, D., Munoz Basagoiti, J., Rodo, J., Elousa, M., Raich Regue, D., Risco, C., Sachse, M., Pino, M., Gumber, S., Paiardini, M., Chojnacki, J., Erkizia, I., Muniz, X., Ballana, E., Riveira Munoz, E., Noguera-Julian, M., Paredes, R., Trinite, B., Tarres Freixas, F., Blanco, I., Guallar, V., Carrillo, J., Blanco, J., Telenti, A., Heyn, H., Segales, J., Clotet, B., Martinez-Picado, J., Vergara-Alert, J., Izquierdo-Useros, N.
10.1101/2021.05.11.443572 — Posted: 2021-05-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).